Clinical trials: Other Drug Substance Abuse
Schizophrenia, Substance Use Disorders
The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients
The lifetime of substance use disorders in schizophrenia is close to 50%. Substance abuse in schizophrenia is associated with negative consequences.
- Trial name
- NCT00295412
- Testing
- quetiapine (drug)
- Where
- Canada
- Sponsor
- Université de Montréal
Cannabis, Alcohol Effect
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study I
The overarching goal of this study is to characterize the effects of ethanol and cannabinoids on simulated driving and related cognition.
- Conditions
- Cannabis, Alcohol Effect, Driving Under the Influence of Alcohol and Other Drugs
- Trial name
- THC-ETOH-I (NCT02709954)
- Testing
- Active inhaled delta-9-THC, Active Oral Ethanol
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Yale University
Schizophrenia, Drug Abuse/Dependency
Influence of Nicotine on Cognitive Function in Schizophrenic Patients With and Without Comorbid Drug Dependence
Background: Individuals with schizophrenia have a significantly higher tendency to develop substance abuse or dependence than the general population.
- Trial name
- NCT01037075
- Where
- 2 sites in United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Schizophrenia, Mood Disorders
Behavioral Treatment of Drug Abuse in Severe and Persistent Mental Illness (SPMI) Patients
The main purpose of this study is to determine if the multifaceted treatment for substance abuse in dual disordered patients is more effective in reducing drug use than a supportive control treatment.
- Conditions
- Schizophrenia, Mood Disorders, Substance Dependence
- Trial name
- NCT00295139
- Testing
- Behavioral Treatment for Substance Abuse in SPMI (BTSAS), Supportive Treatment in Addiction Recovery (STAR), Critical Time Intervention (CTI)
- Where
- 4 sites in United States
- Volunteers
- 293 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Dual Diagnosis
Cannabis and Schizophrenia: Self-Medication and Agonist Treatment
The first aim of this study is to determine whether a brain reward center (BRC) deficiency in patients with schizophrenia (SCZ) and cannabis use disorder (CUD) will be normalized when patients are given cannabis or dronabinol.
- Conditions
- Schizophrenia, Dual Diagnosis, Schizoaffective Disorder, Psychotic Disorder
- Trial name
- NCT00946348
- Testing
- Dronabinol, Cannabis
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia, Drug Abuse
A Pilot, Proof-of-concept Cohort Study of the Prevalence of Comorbid Mental Illness and Substance Abuse
The prevalence estimates for specific mental disorders and illicit drugs have been separately reported in U.S. government surveys.
- Conditions
- Schizophrenia, Drug Abuse, Anxiety Disorder, Bipolar Disorder
- Trial name
- NCT02476877
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Advanced Clinical Laboratory Solutions, Inc.
Cannabis, Alcohol Effect
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study II
The overarching goal of this study is to characterize the effects of ethanol and cannabinoids on simulated driving and related cognition.
- Conditions
- Cannabis, Alcohol Effect, Driving Under the Influence of Alcohol and Other Drugs
- Trial name
- THC-ETOH-II (NCT02710097)
- Testing
- Active inhaled cannabis, Active Oral Ethanol
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Yale University
Healthy, Mental Disorder
I-123 Brain Studies of Serotonin Metabolism in Psychiatric Patients and Normal Volunteers
Abnormalities in the re-uptake of dopamine and serotonin have been described in various neuropsychiatric disorders and substance abuse.
- Conditions
- Healthy, Mental Disorder, Obsessive Compulsive Disorder, Schizophrenia
- Trial name
- NCT00001771
- Where
- United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)